Where’s Lilly’s Alzheimer’s approval?

First it was supposed to happen by the end of 2023. Donanemab, Eli Lilly’s treatment for Alzheimer’s disease, succeeded in its Phase 3 trial and was up for a sure-thing FDA approval in the fourth quarter. Then that timeline shifted to the first quarter of 2024, with no explanation. And now we’re two-thirds into that quarter with no news on what could be among the most important drugs in Lilly’s lengthy history.